Pharming Group Statistics
Total Valuation
Pharming Group has a market cap or net worth of $1.05 billion. The enterprise value is $989.06 million.
| Market Cap | 1.05B |
| Enterprise Value | 989.06M |
Important Dates
The last earnings date was Thursday, March 12, 2026, before market open.
| Earnings Date | Mar 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharming Group has 68.51 million shares outstanding. The number of shares has increased by 6.17% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 68.51M |
| Shares Change (YoY) | +6.17% |
| Shares Change (QoQ) | +50.75% |
| Owned by Insiders (%) | 3.08% |
| Owned by Institutions (%) | 22.20% |
| Float | 664.08M |
Valuation Ratios
The trailing PE ratio is 369.13 and the forward PE ratio is 38.92.
| PE Ratio | 369.13 |
| Forward PE | 38.92 |
| PS Ratio | 2.80 |
| Forward PS | 2.87 |
| PB Ratio | 3.80 |
| P/TBV Ratio | 7.43 |
| P/FCF Ratio | 19.50 |
| P/OCF Ratio | 19.24 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 22.76, with an EV/FCF ratio of 18.33.
| EV / Earnings | 346.92 |
| EV / Sales | 2.63 |
| EV / EBITDA | 22.76 |
| EV / EBIT | 30.68 |
| EV / FCF | 18.33 |
Financial Position
The company has a current ratio of 2.59, with a Debt / Equity ratio of 0.42.
| Current Ratio | 2.59 |
| Quick Ratio | 2.02 |
| Debt / Equity | 0.42 |
| Debt / EBITDA | 2.66 |
| Debt / FCF | 2.15 |
| Interest Coverage | 1.78 |
Financial Efficiency
Return on equity (ROE) is 1.02% and return on invested capital (ROIC) is 2.87%.
| Return on Equity (ROE) | 1.02% |
| Return on Assets (ROA) | 4.48% |
| Return on Invested Capital (ROIC) | 2.87% |
| Return on Capital Employed (ROCE) | 8.39% |
| Weighted Average Cost of Capital (WACC) | 4.91% |
| Revenue Per Employee | $931,025 |
| Profits Per Employee | $7,057 |
| Employee Count | 404 |
| Asset Turnover | 0.84 |
| Inventory Turnover | 0.75 |
Taxes
In the past 12 months, Pharming Group has paid $10.31 million in taxes.
| Income Tax | 10.31M |
| Effective Tax Rate | 80.25% |
Stock Price Statistics
The stock price has increased by +72.10% in the last 52 weeks. The beta is 0.16, so Pharming Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.16 |
| 52-Week Price Change | +72.10% |
| 50-Day Moving Average | 17.05 |
| 200-Day Moving Average | 14.62 |
| Relative Strength Index (RSI) | 44.40 |
| Average Volume (20 Days) | 22,250 |
Short Selling Information
The latest short interest is 11,389, so 0.02% of the outstanding shares have been sold short.
| Short Interest | 11,389 |
| Short Previous Month | 9,071 |
| Short % of Shares Out | 0.02% |
| Short % of Float | 0.00% |
| Short Ratio (days to cover) | 0.33 |
Income Statement
In the last 12 months, Pharming Group had revenue of $376.13 million and earned $2.85 million in profits. Earnings per share was $0.00.
| Revenue | 376.13M |
| Gross Profit | 330.63M |
| Operating Income | 32.24M |
| Pretax Income | 12.85M |
| Net Income | 2.85M |
| EBITDA | 43.46M |
| EBIT | 32.24M |
| Earnings Per Share (EPS) | $0.00 |
Balance Sheet
The company has $179.10 million in cash and $115.78 million in debt, with a net cash position of $63.33 million or $0.92 per share.
| Cash & Cash Equivalents | 179.10M |
| Total Debt | 115.78M |
| Net Cash | 63.33M |
| Net Cash Per Share | $0.92 |
| Equity (Book Value) | 277.10M |
| Book Value Per Share | 0.42 |
| Working Capital | 183.68M |
Cash Flow
In the last 12 months, operating cash flow was $54.71 million and capital expenditures -$749,000, giving a free cash flow of $53.96 million.
| Operating Cash Flow | 54.71M |
| Capital Expenditures | -749,000 |
| Depreciation & Amortization | 11.22M |
| Net Borrowing | -4.25M |
| Free Cash Flow | 53.96M |
| FCF Per Share | $0.79 |
Margins
Gross margin is 87.90%, with operating and profit margins of 8.57% and 0.76%.
| Gross Margin | 87.90% |
| Operating Margin | 8.57% |
| Pretax Margin | 3.42% |
| Profit Margin | 0.76% |
| EBITDA Margin | 11.55% |
| EBIT Margin | 8.57% |
| FCF Margin | 14.35% |
Dividends & Yields
Pharming Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.17% |
| Shareholder Yield | -6.17% |
| Earnings Yield | 0.27% |
| FCF Yield | 5.13% |
Analyst Forecast
The average price target for Pharming Group is $39.00, which is 153.91% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $39.00 |
| Price Target Difference | 153.91% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 12.81% |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pharming Group has an Altman Z-Score of 2.8 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.8 |
| Piotroski F-Score | 5 |